Pressure-sensitive adhesives (PSAs) are adhesives that are capable of bonding to surfaces when light pressure is briefly applied. PSA's are used for medicinal patches, medical devices, tapes, dressings and bioelectrodes. PSAs must provide adequate...

Pressure-sensitive adhesives (PSAs) are adhesives that are capable of bonding to surfaces when light pressure is briefly applied. PSA's are used for medicinal patches, medical devices, tapes, dressings and bioelectrodes. PSAs must provide adequate skin adhesion and cohesion; biocompatibility (be biologically inert to preclude contact dermatitis, allergy, sensitivity or toxicity; repositioning ability on the skin surface for multiple applications; small geometric dimensions; reasonable cost; and compliance with international pharmaceutical standards. Keywords: bandages

Patches derived from tree gum exudate for transdermal and topical drug delivery

Category	Topical and transdermal drug delivery system
Development Stage	In vivo and in vitro results
Patent Status	U.S. patent filed
Market Size	Annual U.S. market for transdermal patches alone is more than $3 billion

Highlights

• Proprietary adhesive patches for novel drug delivery with improved patch-skin adhesion and biocompatibility.
• Work in a range of pHs, provide better adhesion and higher permeation than commercial patches.
• Proof of concept was shown in several in-vivo and in-vitro models.
• These novel patches will serve as a platform for transdermal and topical drug delivery.

Our Innovation

The patches are adhesives based on chemically and physically modified polysaccharides, which are partially depolymerised providing a more effective topical and transdermal drug delivery system. All tested patches were found to be highly adhesive while providing superior drug penetration.

Key Features

• Novel and natural drug carrier applicable for a broad range of drugs
• More effective topical and transdermal drug delivery system
• Improved adhesiveness and elasticity
• Superior drug delivery
• High manufacturability, entailing flexible pricing strategy
• All exudates used are generally recognized as safe (GRAS) and are FDA approved

Development Milestones

In vivo studies testing various compositions of the patches enhancing adhesiveness and drug permeability

The Opportunity

• Annual U.S. market for transdermal patches alone is more than $3 billion[1].
• Replace current commercial patches applying many of the currently used drugs such as clonidine, fentanyl, lidocaine, nicotine, nitroglycerin, oestradiol, oxybutinin, scopolamine, and testosterone.
• The number of drug therapies being developed in patch form is expanding.

project-id 6-2006-40

U.S. patent filed